Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2015 4
2016 1
2017 8
2018 5
2019 6
2020 11
2021 13
2022 10
2023 12
2024 9
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
A cure for the kiss of death?
Appelbaum JS, Percival ME, Scott BL. Appelbaum JS, et al. Among authors: percival me. Blood Adv. 2025 Jun 10;9(11):2855-2856. doi: 10.1182/bloodadvances.2025015850. Blood Adv. 2025. PMID: 40493363 No abstract available.
Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samples.
Raychaudhuri S, Gem H, Chung K, McLean JS, Kerns KA, Hullar MAJ, Elmorr E, Appelbaum JB, Percival MM, Walter RB, Halpern AB, Minot SS, Kim K, Zevin AS, Rashidi A. Raychaudhuri S, et al. NPJ Biofilms Microbiomes. 2025 May 26;11(1):88. doi: 10.1038/s41522-025-00725-7. NPJ Biofilms Microbiomes. 2025. PMID: 40419513 Free PMC article.
Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment.
Wu M, Russell K, Shaw CM, Halpern AB, Ghiuzeli C, Appelbaum JS, Hendrie P, Walter RB, Percival MM. Wu M, et al. JCO Oncol Pract. 2025 Apr 3:OP2400734. doi: 10.1200/OP-24-00734. Online ahead of print. JCO Oncol Pract. 2025. PMID: 40179338
These patients were more frequently male, older than 60 years, had preexisting cardiovascular risk factors, and leukemias of higher risk. Ischemia-related systolic failure was associated with nonrecovery (B = -2.89, P = .005), whereas chemotherapy-related dysfunction was a …
These patients were more frequently male, older than 60 years, had preexisting cardiovascular risk factors, and leukemias of higher r …
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
Wuliji N, Jones SMW, Gooley TA, Gerds AT, Medeiros BC, Shami PJ, Galvin JP, Adekola KUA, Luger SM, Baer MR, Rizzieri DA, Wildes T, Wang ES, Sekeres MA, Mukherjee S, Smith J, Garrison M, Kojouri K, Appelbaum JS, Percival MM, Sandmaier BM, Lee SJ, Appelbaum F, Rouce RH, Sorror ML. Wuliji N, et al. Blood. 2025 Mar 11:blood.2024027543. doi: 10.1182/blood.2024027543. Online ahead of print. Blood. 2025. PMID: 40067123
Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible regardless of social determinants of health (SDOH) remains unknown. ...
Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible rega …
Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia.
Pal KV, Othus M, Ali Z, Russell K, Shaw C, Percival MM, Hendrie PC, Appelbaum JS, Walter RB, Halpern AB. Pal KV, et al. Blood Adv. 2024 Dec 24;8(24):6161-6170. doi: 10.1182/bloodadvances.2024014291. Blood Adv. 2024. PMID: 39368804 Free PMC article.
Febrile neutropenia (FN) is the most common reason for hospital readmission after chemotherapy for acute myeloid leukemia (AML) and is a major driver of health care resource utilization. Although FN risk models exist, they have largely been developed and validated f …
Febrile neutropenia (FN) is the most common reason for hospital readmission after chemotherapy for acute myeloid leukemia (AML …
Second chances for secondary AML.
Appelbaum JS, Appelbaum FR, Percival ME. Appelbaum JS, et al. Among authors: percival me. Blood Adv. 2024 Aug 13;8(15):4221-4222. doi: 10.1182/bloodadvances.2024013318. Blood Adv. 2024. PMID: 39136970 Free PMC article. No abstract available.
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
Zhang MY, Othus M, McMillen K, Erba HP, Garcia-Manero G, Pagel JM, Sorror ML, Percival MM. Zhang MY, et al. Leukemia. 2024 Jul;38(7):1488-1493. doi: 10.1038/s41375-024-02288-6. Epub 2024 Jun 3. Leukemia. 2024. PMID: 38830960
There has been ongoing debate on the association between obesity and outcomes in acute myeloid leukemia (AML). Currently few studies have stratified outcomes by class I obesity, class II obesity, and class III obesity, and a more nuanced understanding is becoming in …
There has been ongoing debate on the association between obesity and outcomes in acute myeloid leukemia (AML). Currently few s …
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
Kopmar NE, Quach K, Gooley TA, Martino CH, Cherian S, Percival MM, Halpern AB, Ghiuzeli CM, Oehler VG, Abkowitz JL, Walter RB, Cassaday RD. Kopmar NE, et al. JAMA Oncol. 2024 Jul 1;10(7):961-965. doi: 10.1001/jamaoncol.2024.0967. JAMA Oncol. 2024. PMID: 38722664 Free PMC article. Clinical Trial.
IMPORTANCE: Options for adults with relapsed or refractory B-cell acute lymphoblastic leukemia or lymphoma (B-ALL) are limited, and new approaches are needed. Inotuzumab ozogamicin (InO) has been combined with low-intensity chemotherapy, with modest improvements over histo …
IMPORTANCE: Options for adults with relapsed or refractory B-cell acute lymphoblastic leukemia or lymphoma (B-ALL) are limited, and n …
73 results